HUTCHMED (China) Ltd - ESG Rating & Company Profile powered by AI
The ESG score covers 17 UN SDGs including: 'Quality Education', 'Responsible Production & Consumption' and 'Life on Land'. The webpage of HUTCHMED (China) Ltd is assembled by All Street Sevva using cutting edge machine learning. The SDG rating for HUTCHMED (China) Ltd represents the company's reporting of the UN Sustainable Development Goals.
HUTCHMED (China) Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.7; made up of an environmental score of 6.9, social score of 6.0 and governance score of 7.0.
6.7
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 432 | Twist Bioscience Corp | 6.8 | High |
| 432 | Rhythm Pharmaceuticals Inc | 6.8 | High |
| 446 | HUTCHMED (China) Ltd | 6.7 | High |
| 446 | Actinium Pharmaceuticals Inc | 6.7 | High |
| 446 | AnGes Inc | 6.7 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does HUTCHMED (China) Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes HUTCHMED (China) Ltd report the average age of the workforce?
Sign up for free to unlockDoes HUTCHMED (China) Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes HUTCHMED (China) Ltd offer flexible work?
Sign up for free to unlockDoes HUTCHMED (China) Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes HUTCHMED (China) Ltd conduct supply chain audits?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes HUTCHMED (China) Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose water use targets?
Sign up for free to unlockDoes HUTCHMED (China) Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid HUTCHMED (China) Ltd have a product recall in the last two years?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes HUTCHMED (China) Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas HUTCHMED (China) Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose parental leave metrics?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes HUTCHMED (China) Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes HUTCHMED (China) Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs HUTCHMED (China) Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose its waste policy?
Sign up for free to unlockDoes HUTCHMED (China) Ltd report according to TCFD requirements?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose energy use targets?
Sign up for free to unlockDoes HUTCHMED (China) Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes HUTCHMED (China) Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for HUTCHMED (China) Ltd
These potential risks are based on the size, segment and geographies of the company.
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.